Therapeutic effect of vitamin D2 on cardiac autonomic neuropathy in type 2 diabetes
Guo Wei
Shi Xiaoxia
Liu Dexue
Zheng Yueyue
Li Ruige
Abstract：Objective To investigate the clinical efficacy of vitamin D2 (VD2) in the treatment of diabetic cardiac autonomic neuropathy (DCAN). Methods 240 patients with DCAN were divided into control group (n=80), low-dose group (n=80) and high-dose group (n=80) according to the same gender, age difference less than 5 years, and disease path difference less than 3 years. Based on basic treatment, the control group was injected with 0.9 ml of 0.9% sodium chloride. The low-dose group and the high-dose group were intramuscularly injected with vitamin D2 (7.5 mg in the low-dose group and 15 mg in the high-dose group), once every 2 weeks for 1 year. Heart rate variability (HRV) index including standard deviation of normal to normal (SDNN), standard deviation of the average normal to normal (SDANN), root mean square of successive RR-interval differences (RMSSD), the proportion of interval differences of successive normal-beat to normal-beat intervals greater than 50 ms (PNN50), and 25(OH) D3 concentration before treatment, after treatment and after 1 year of treatment were observed and compared, as well as effectiveness of treatment. Results There were no significant differences in pre-treatment general data, heart rate variability (SDNN, SDANN, RMSSD, PNN50), 25(OH)D3, and VD deficiency rates among the three groups (P>0.05). Compared with before treatment, at the end of treatment and 1 year after treatment, the SDNN increased, SDANN decreased, RMSSD and PNN50 increased, 25(OH)D3 level increased, and VD deficiency rate decreased. The difference was statistically significant (P<0.05). PNN50 and 25(OH)D3 levels were decreased after 1 year of treatment in the low-dose group compared with the end of treatment, and the difference was statistically significant (P<0.05). Compared with before treatment, at the end of treatment and 1 year after treatment, the SDNN increased, SDANN decreased, RMSSD and PNN50 increased, 25(OH)D3 level increased, and VD deficiency rate decreased. The above differences were statistically significant (P<0.05). Compared with the end of treatment, SDNN, SDANN, RMSSD and PNN50 were decreased in the high-dose group after 1 year of treatment, and the difference was statistically significant (P<0.05). At the end of treatment and after 1 year of treatment, compared with the control group, the SDNN, SDANN, RMSSD and PNN50 increased, the 25(OH)D3 level increased, and the VD deficiency rate decreased in the low-dose group and the high-dose group. The difference was statistically significant (P<0.05). Among them, the change in the high-dose group was more obvious, compared with the low-dose group, the difference was statistically significant (P<0.05); the high-dose group at the end of treatment and after 1 year of treatment, the treatment of the less effective dose group and the control There were significant differences in the group, and the differences were statistically significant (P<0.05). Conclusions VD2 treatment of type 2 diabetes with DCAN is effective, can significantly improve the nutritional status and heart rate variability of patients with VD, and the effect is dose-related, high dose (15 mg) has a better effect.
Keywords：Type 2 diabetesCardiac autonomic neuropathy: Vitamin D2
Publication Date：2019-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 950-953 )